Drugs / 89Zr-LNCab103
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07023848 | Jul 2025 → Jul 2026 overdue | breast cancer, gastric cancer, urothelial carcinoma | Affiliated Hospital of Jiangnan University | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-LNCab103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07023848 ↗ |
| Modality | Diagnostic / imaging agent | “89Zr-labeled HER2-targeted antibody fragments in diagnosis and screening” NCT07023848 ↗ |
| Route | Intravenous | “89Zr-LNCab103 injection (1-3mCi) was injected intravenously for 45-60s.” NCT07023848 ↗ |